Trimel Pharma inks $10.5 mln deal with West Face Capital, First Generation Capital
Trimel Pharmaceuticals Corp (TSX: TRL), a Mississauga, Ont.-based specialty pharmaceutical company that develops medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders, has completed a private placement. The investment, which generated gross proceeds of more than $10.5 million, was provided by First Generation Capital and West Face Capital. The funds will allow Trimel to focus on key operational objectives and milestones. Toronto-based private investment firm West Face Capital last month initially closed its West Face Alternative Credit Fund Group at around $400 million in commitments.
24 February 2014•2 mins read
